EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management

Ayalew Tefferi iD, Tiziano Barbui iD

American Journal of Hematology · 2023-09 · 98 (9) · 1465-1487

DOI: 10.1002/ajh.27002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 26.06.2023. Verfasst von Ayalew Tefferi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Polycythemia Vera, Thrombocythemia, Essential, Thrombosis, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 236-mal zitiert (Crossref) und nennt 206 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disease Overview Polycythemia vera (PV) is a JAK2 ‐mutated myeloproliferative neoplasm characterized by clonal erythrocytosis; other features include leukocytosis, thrombocytosis, splenomegaly, pruritus, constitutional symptoms, microcirculatory disturbances, and increased risk of thrombosis and progression into myelofibrosis (post‐PV MF) or acute myeloid leukemia (AML). Diagnosis A working diagnosis is considered in the presence of a JAK2 mutation associated with hemoglobin/hematocrit levels of >16.5 g/dL/49% in men or 16 g/dL/48% in women; morphologic confirmation by bone marrow examination is advised but not mandated. Cytogenetics Abnormal karyotype is seen in 15%–20% of patients with the most frequent sole abnormalities being +9 (5%), loss of chromosome Y (4%), +8 (3%), and 20q− (3%). Mutations Over 50% of patients harbor DNA sequence variants/mutations other than JAK2 , with the most frequent being TET2 (18%) and ASXL1 (15%). Prognostically adverse mutations include SRSF2, IDH2, RUNX1 , and U2AF1 , with a combined incidence of 5%–10%. Survival and Prognosis Median survival is ⁓15 years but exceeds 35 years for patients aged ≤40 years. Risk factors for survival include older age, leukocytosis, abnormal karyotype, and the presence of adverse mutations. Twenty‐year risk for thrombosis, post‐PV MF, or AML are ⁓26%, 16% and 4%, respectively. Risk Factors for Thrombosis Two risk categories are considered: high (age >60 years or thrombosis history) and low (absence of both risk factors). Additional predictors for arterial thrombosis include cardiovascular risk factors and for venous thrombosis higher absolute neutrophil count and JAK2 V617F allele burden. Treatment Current goal of therapy is to prevent thrombosis. Periodic phlebotomy, with a hematocrit target of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycythemia VeraThrombocythemia, EssentialThrombosisLeukemia, Myeloid, AcuteMaleHumansFemaleBusulfanLeukocytosisMicrocirculationJanus Kinase 2NitrilesPyrazolesPyrimidines

Substanzen

BusulfanJanus Kinase 2ruxolitinibNitrilesPyrazolesPyrimidines

Autor:innen und Institutionen

  • Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.

ORCID-Profile: Ayalew Tefferi, Tiziano Barbui

Zitieren

APA

Tefferi, A., & Barbui, T. (2023). Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management. American Journal of Hematology, 98(9), 1465-1487. https://doi.org/10.1002/ajh.27002

Vancouver

Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management. American Journal of Hematology. 2023;98(9):1465-1487. doi:10.1002/ajh.27002

BibTeX
@article{Tefferi2023,
  author = {Tefferi, Ayalew and Barbui, Tiziano},
  title = {Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management},
  journal = {American Journal of Hematology},
  year = {2023},
  volume = {98},
  number = {9},
  pages = {1465--1487},
  doi = {10.1002/ajh.27002}
}
Kostenlos starten →